GPGA
ESPR icon

Grandeur Peak Global Advisors’s Esperion Therapeutics ESPR Stock Holding History

Grandeur Peak Global Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3,200
Closed -$60K – 120
2013
Q3 		$60K Buy
+3,200
New +$53.8K 0.02% 111

Other funds holding ESPR

Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Polar Capital
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Grandeur Peak Global Advisors's ESPR Position: Q4 2013 in Review

Grandeur Peak Global Advisors sold out of Esperion Therapeutics (ESPR) in Q4 2013, closing a stake of 3,200 shares — an estimated $60K sold.

Grandeur Peak Global Advisors first reported a position in ESPR in Q3 2013 and held it in 1 quarter. The position peaked at $60K in Q3 2013. 44 funds tracked by Wall St. Rank hold ESPR as of Q4 2013.

  • Grandeur Peak Global Advisors reported no remaining Esperion Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Grandeur Peak Global Advisors sold 3,200 Esperion Therapeutics shares in Q4 2013, an estimated $60K.
  • Grandeur Peak Global Advisors first reported a position in Esperion Therapeutics in Q3 2013 and held it in 1 quarter.
  • Grandeur Peak Global Advisors's Esperion Therapeutics position peaked at $60K in Q3 2013.
  • 44 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2013.

Based on Grandeur Peak Global Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.